Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations

Rhea-AI Filing Summary

Immunovant, Inc. Chief Technology Officer Jay S. Stout reported selling a total of 10,132 shares of common stock on April 8, 2026, at a weighted average price of $24.83 per share. According to the footnotes, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units.

The filing states that part of the sale related to 19,045 RSUs that vested on April 1, 2026, from a 76,181-RSU grant made on April 1, 2025, and part related to 3,436 RSUs that vested on April 2, 2026, from a 54,978-RSU grant made on April 2, 2024. After these transactions, Stout directly holds 254,439 shares of Immunovant common stock.

Insights

Equity compensation analyst

Immunovant CTO’s Form 4 shows routine tax-related share sales from RSU vesting, not a discretionary stock sale.

The Form 4 reports that Jay S. Stout, Immunovant’s Chief Technology Officer, sold 10,132 shares of common stock at a weighted average of $24.83 per share. Footnotes explain the transactions funded tax withholding on vesting restricted stock units granted in 2024 and 2025.

The company elected a mandatory "sell to cover" method, so the disposition was not a discretionary market-timing decision by the insider. After these sales, Stout still holds 254,439 shares directly, indicating he retains a substantial equity position in Immunovant.

Insider Trade Summary

Net Seller: 10,132 shares ($251,578)

Net Sell 2 txns

Insider Stout Jay S

Role Chief Technology Officer

Sold 10,132 shs ($252K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,614	$24.83	$214K
Sale	Common Stock	1,518	$24.83	$38K

Holdings After Transaction: Common Stock — 255,957 shares (Direct)

Footnotes (1)

1. On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on April 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Key Figures

Shares sold: 10,132 shares Weighted average sale price: $24.83 per share Shares held after transaction: 254,439 shares +5 more

8 metrics

Shares sold 10,132 shares Common stock sold on April 8, 2026

Weighted average sale price $24.83 per share Open-market sales on April 8, 2026

Shares held after transaction 254,439 shares Direct ownership after reported sales

2025 RSU grant 76,181 RSUs Granted on April 1, 2025

2025 RSUs vested 19,045 RSUs Vested on April 1, 2026

2024 RSU grant 54,978 RSUs Granted on April 2, 2024

2024 RSUs vested 3,436 RSUs Vested on April 2, 2026

Sale price range $24.54 - $25.39 per share Range of individual trade prices

Key Terms

restricted stock units ("RSUs"), sell to cover, weighted average price, tax withholding obligations, +1 more

5 terms

restricted stock units ("RSUs") financial

"the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting"

Form 4 regulatory

"as previously reported on a Form 4 filed on April 3, 2025"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stout Jay S

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		S		8,614(1)	D	$24.83(2)	255,957	D
Common Stock	04/08/2026		S		1,518(3)	D	$24.83(2)	254,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 19,045 of these RSUs vested on April 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.54 - $25.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. On April 2, 2024, the holder was granted 54,978 RSUs, as previously reported on a Form 4 filed on April 4, 2024, of which 3,436 of these RSUs vested on April 2, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Jay Stout	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunovant (IMVT) CTO Jay Stout report in this Form 4 filing?

Jay S. Stout reported selling 10,132 Immunovant common shares on April 8, 2026, at a weighted average price of $24.83 per share. The filing explains these sales were to cover tax withholding obligations arising from vesting restricted stock units granted in 2024 and 2025.

Were the IMVT insider stock sales by the CTO discretionary or tax-related?

The reported sales were tax-related, not discretionary trades. Footnotes state Immunovant required a "sell to cover" transaction so shares would be sold automatically to fund tax withholding when the CTO’s restricted stock units vested and settled in April 2026.

How many Immunovant shares does the CTO hold after these Form 4 transactions?

After completing the tax-related sales, Chief Technology Officer Jay S. Stout directly holds 254,439 shares of Immunovant common stock. This post-transaction holding reflects his remaining equity stake following the 10,132 shares sold to satisfy required tax withholding on vested RSUs.

At what price did the Immunovant CTO’s Form 4 report the shares were sold?

The Form 4 reports a weighted average price of $24.83 per share for the 10,132 shares sold. A footnote adds that individual trades occurred in a range from $24.54 to $25.39 per share, and detailed pricing information is available upon request.

What RSU grants are connected to the Immunovant CTO’s April 2026 share sales?

The sales relate to RSUs granted on April 1, 2025 and April 2, 2024. From the 2025 grant of 76,181 RSUs, 19,045 vested on April 1, 2026. From the 2024 grant of 54,978 RSUs, 3,436 vested on April 2, 2026, triggering tax-withholding sales.

Why did the Immunovant CTO use a sell-to-cover method for RSU vesting?

Footnotes state the issuer elected to require tax withholding obligations to be funded by a "sell to cover" transaction. This means shares are automatically sold at vesting to pay taxes, so the reported sales do not represent a discretionary investment decision by the CTO.